Literature DB >> 26334580

Hic-5 deficiency attenuates the activation of hepatic stellate cells and liver fibrosis through upregulation of Smad7 in mice.

Xiao-Feng Lei1, Wenguang Fu2, Joo-Ri Kim-Kaneyama3, Tomokatsu Omoto1, Takuro Miyazaki1, Bo Li4, Akira Miyazaki1.   

Abstract

BACKGROUND & AIM: Hydrogen peroxide-inducible clone-5 (Hic-5), also named as transforming growth factor beta-1-induced transcript 1 protein (Tgfb1i1), was found to be induced by TGF-β. Previous studies have shown that TGF-β is a principal mediator of hepatic stellate cell (HSC) activation in liver fibrosis. However, this process remains elusive. In this study, we aimed to define the role of Hic-5 in HSC activation and liver fibrosis.
METHODS: We examined the expression levels of Hic-5 during HSCs activation and in fibrotic liver tissues by quantitative real-time reverse transcriptase polymerase chain reaction, Western blot and immunohistochemistry. Hic-5 knockout (KO) and wild-type (WT) mice were subjected to bile duct ligation (BDL) or carbon tetrachloride (CCl4) injection to induce liver fibrosis.
RESULTS: Hic-5 expression was strongly upregulated in activated HSCs of the human fibrotic liver tissue and BDL or CCl4-induced mouse liver fibrosis. Hic-5 deficiency significantly attenuated mouse liver fibrosis and HSC activation. Furthermore, Hic-5 knockdown by siRNA in vivo repressed CCl4-induced liver fibrosis in mice. Mechanistically, the absence of Hic-5 significantly inhibited the TGF-β/Smad2 signaling pathway, proved by increasing Smad7 expression, resulting in reduced collagen production and α-smooth muscle actin expression in the activated HSCs.
CONCLUSION: Hic-5 deficiency attenuates the activation of HSCs and liver fibrosis though reducing the TGF-β/Smad2 signaling by upregulation of Smad7. Thus, Hic-5 can be regarded as a potential therapeutic target for liver fibrosis.
Copyright © 2015 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Hepatic stellate cells; Hic-5; Liver fibrosis; Smad2; Smad7; Tgfb1i1

Mesh:

Substances:

Year:  2015        PMID: 26334580     DOI: 10.1016/j.jhep.2015.08.026

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  21 in total

1.  IL-17-driven intestinal fibrosis is inhibited by Itch-mediated ubiquitination of HIC-5.

Authors:  J Paul; A K Singh; M Kathania; T L Elviche; M Zeng; V Basrur; A L Theiss; K Venuprasad
Journal:  Mucosal Immunol       Date:  2017-06-14       Impact factor: 7.313

2.  Hic-5 is required for myofibroblast differentiation by regulating mechanically dependent MRTF-A nuclear accumulation.

Authors:  Scott D Varney; Courtney B Betts; Rui Zheng; Lei Wu; Boris Hinz; Jiliang Zhou; Livingston Van De Water
Journal:  J Cell Sci       Date:  2016-01-12       Impact factor: 5.285

Review 3.  siRNA- and miRNA-based therapeutics for liver fibrosis.

Authors:  Zhen Zhao; Chien-Yu Lin; Kun Cheng
Journal:  Transl Res       Date:  2019-08-13       Impact factor: 7.012

4.  Implementing genetic screening for the management of hepatic disease.

Authors:  Brittany Dewdney; Lionel Hebbard
Journal:  Hepatobiliary Surg Nutr       Date:  2017-10       Impact factor: 7.293

5.  Emodin ameliorates renal fibrosis in rats via TGF-β1/Smad signaling pathway and function study of Smurf 2.

Authors:  Libin Ma; Hua Li; Shuchao Zhang; Xiaoling Xiong; Kean Chen; Peiwu Jiang; Kang Jiang; Gang Deng
Journal:  Int Urol Nephrol       Date:  2017-12-11       Impact factor: 2.370

6.  Praziquantel ameliorates CCl4 -induced liver fibrosis in mice by inhibiting TGF-β/Smad signalling via up-regulating Smad7 in hepatic stellate cells.

Authors:  Jinfeng Liu; Delong Kong; Jingfan Qiu; Yanci Xie; Zhongkui Lu; Chunlei Zhou; Xinjian Liu; Rong Zhang; Yong Wang
Journal:  Br J Pharmacol       Date:  2019-12-29       Impact factor: 8.739

7.  The impact of stromal Hic-5 on the tumorigenesis of colorectal cancer through lysyl oxidase induction and stromal remodeling.

Authors:  Tomokatsu Omoto; Joo-Ri Kim-Kaneyama; Xiao-Feng Lei; Akira Orimo; Koji Ohnishi; Kosuke Yoshihara; Aya Miyauchi; Shuo Li; Lin Gao; Takahiro Umemoto; Junichi Tanaka; Kenta Nakahara; Motohiro Takeya; Fumio Ishida; Shin-Ei Kudo; Shogo Haraguchi; Takuro Miyazaki; Akira Miyazaki
Journal:  Oncogene       Date:  2017-12-15       Impact factor: 9.867

8.  MiR-216a accelerates proliferation and fibrogenesis via targeting PTEN and SMAD7 in human cardiac fibroblasts.

Authors:  Jinsong Tao; Jingyi Wang; Chunyu Li; Weiwei Wang; Hao Yu; Jinhui Liu; Xiangqing Kong; Yan Chen
Journal:  Cardiovasc Diagn Ther       Date:  2019-12

Review 9.  Liver fibrosis and hepatic stellate cells: Etiology, pathological hallmarks and therapeutic targets.

Authors:  Chong-Yang Zhang; Wei-Gang Yuan; Pei He; Jia-Hui Lei; Chun-Xu Wang
Journal:  World J Gastroenterol       Date:  2016-12-28       Impact factor: 5.742

10.  Microarray Study of Pathway Analysis Expression Profile Associated with MicroRNA-29a with Regard to Murine Cholestatic Liver Injuries.

Authors:  Sung-Chou Li; Feng-Sheng Wang; Ya-Ling Yang; Mao-Meng Tiao; Jiin-Haur Chuang; Ying-Hsien Huang
Journal:  Int J Mol Sci       Date:  2016-03-01       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.